Logo image
Moving forward: a mucosal vaccine against group A streptococcus
Journal article   Peer reviewed

Moving forward: a mucosal vaccine against group A streptococcus

M M Georgousakis, David J McMillan, M R Batzloff and K S Sriprakash
Expert Review of Vaccines, Vol.8(6), pp.747-760
2009
url
https://doi.org/10.1586/erv.09.33View
Published Version

Abstract

mucosal adjuvant mucosal delivery mucosal immunity Streptococcus pyogenes vaccine
Streptococcus pyogenes, commonly referred to as group A streptococcus (GAS), colonizes the epithelial surfaces of the upper respiratory tract and the skin, where it causes a myriad of diseases that vary in clinical presentation and severity. Several candidate GAS vaccines are now approaching or have entered human clinical trials. However, the preclinical evaluation for the leading vaccine candidates has been premised on their ability to induce systemic protection through parenteral immunization. While systemic immunity has proven effective in preventing GAS dissemination and associated disease, it may not prove to be the optimal approach for inducing mucosal immunity against GAS. With this in mind, many researchers are moving toward testing the efficacy of their GAS vaccine candidate when delivered to the mucosal surface. This review discusses the interaction of GAS with the mucosal immune system and the approaches taken thus far in developing a mucosal GAS vaccine.

Details

Metrics

4 File views/ downloads
529 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Immunology

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Logo image